CTOs on the Move

Charlotte's Optical Co Inc

www.charlottesoptical.com

 
Charlotte's Optical Co Inc is a Colorado Springs, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

New West Health Services

At New West, we believe it makes more sense to help you stay healthy rather than just caring for you after you've become sick or injured. That's why we've developed a full line of products to give you the best choice in group and individual health care

American Viatical Svc

American Viatical Svc is a Woodstock, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AIM Healthcare Services

To reduce the cost of healthcare and simplify healthcare information management.

Cellanyx

Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.